(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 44.45% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Zymeworks's revenue in 2026 is $81,263,000.On average, 14 Wall Street analysts forecast ZYME's revenue for 2026 to be $22,839,422,789, with the lowest ZYME revenue forecast at $17,540,139,252, and the highest ZYME revenue forecast at $30,483,476,814. On average, 13 Wall Street analysts forecast ZYME's revenue for 2027 to be $16,440,411,954, with the lowest ZYME revenue forecast at $9,374,700,571, and the highest ZYME revenue forecast at $27,579,349,678.
In 2028, ZYME is forecast to generate $17,884,808,100 in revenue, with the lowest revenue forecast at $11,443,443,889 and the highest revenue forecast at $27,909,413,914.